Dimensional Fund Advisors LP Purchases 89,250 Shares of STERIS plc $STE

Dimensional Fund Advisors LP grew its position in STERIS plc (NYSE:STE) by 9.4% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,039,351 shares of the medical equipment provider’s stock after buying an additional 89,250 shares during the quarter. Dimensional Fund Advisors LP owned 1.06% of STERIS worth $257,157,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. Mediolanum International Funds Ltd raised its holdings in shares of STERIS by 9.0% in the second quarter. Mediolanum International Funds Ltd now owns 62,327 shares of the medical equipment provider’s stock valued at $14,883,000 after acquiring an additional 5,156 shares in the last quarter. Entropy Technologies LP grew its holdings in STERIS by 282.2% during the 2nd quarter. Entropy Technologies LP now owns 9,099 shares of the medical equipment provider’s stock worth $2,186,000 after acquiring an additional 6,718 shares in the last quarter. Vanguard Group Inc. grew its holdings in STERIS by 1.7% during the 2nd quarter. Vanguard Group Inc. now owns 12,163,128 shares of the medical equipment provider’s stock worth $2,921,827,000 after acquiring an additional 205,276 shares in the last quarter. Asset Management One Co. Ltd. increased its position in STERIS by 5.4% during the 3rd quarter. Asset Management One Co. Ltd. now owns 98,487 shares of the medical equipment provider’s stock valued at $24,366,000 after purchasing an additional 5,072 shares during the period. Finally, Cerity Partners LLC increased its position in STERIS by 28.8% during the 3rd quarter. Cerity Partners LLC now owns 96,853 shares of the medical equipment provider’s stock valued at $23,966,000 after purchasing an additional 21,656 shares during the period. Institutional investors own 94.69% of the company’s stock.

STERIS Stock Performance

STE stock opened at $230.49 on Friday. STERIS plc has a one year low of $204.90 and a one year high of $269.44. The firm has a market cap of $22.60 billion, a price-to-earnings ratio of 32.15 and a beta of 1.05. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.75 and a current ratio of 2.48. The firm has a 50-day simple moving average of $254.37 and a two-hundred day simple moving average of $251.51.

STERIS (NYSE:STE) last issued its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $2.53 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $2.53. STERIS had a net margin of 12.15% and a return on equity of 14.34%. The business’s revenue was up 9.2% compared to the same quarter last year. During the same period in the prior year, the company posted $2.32 EPS. STERIS has set its FY 2026 guidance at 10.150-10.300 EPS. On average, equities analysts forecast that STERIS plc will post 9.08 EPS for the current fiscal year.

STERIS Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, March 19th. Shareholders of record on Tuesday, February 17th will be issued a $0.63 dividend. This represents a $2.52 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Tuesday, February 17th. STERIS’s payout ratio is currently 35.15%.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on STE shares. Weiss Ratings reaffirmed a “buy (b)” rating on shares of STERIS in a research report on Friday, January 9th. Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a report on Saturday. Six analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $275.20.

Insider Transactions at STERIS

In other news, Director Cynthia L. Feldmann sold 3,098 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $237.21, for a total transaction of $734,876.58. Following the transaction, the director directly owned 705 shares of the company’s stock, valued at approximately $167,233.05. This represents a 81.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.07% of the company’s stock.

STERIS Company Profile

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.